Quick Summary
Covering the latest research from top Wall Street investment banks

Equity Market Rotation Is Spreading Further as Semiconductor Momentum Starts to Cool

Institution
Morgan Stanley
Date
2026-07-06
Authors
Michael J Wilson, Andrew B Pauker, Michelle M. Weaver, CFA, Diane Ding, Ph.D., Nicholas Lentini, CFA
Company
-
Ticker
-
Industry
US Equity Strategy
Rating
-
NeutralLow confidenceThe report argues market leadership is broadening as oil prices fall, rate expectations become less hawkish, and semiconductor momentum weakens, while favoring Consumer Discretionary Goods, Transports, Biotech and Hyperscalers over Semiconductors.
AuthorsMichael J Wilson, Andrew B Pauker, Michelle M. Weaver, CFA, Diane Ding, Ph.D., Nicholas Lentini, CFA
CoverageUnited States
Business segmentsSemiconductors、Hyperscalers、Consumer Discretionary Goods、Transports、Regional Banks、Biotechnology
Research firm divisions/subsidiariesMorgan Stanley(Other)、Morgan Stanley & Co. LLC(Other)

AI summary card

Equity Market Rotation Is Spreading Further as Semiconductor Momentum Starts to Cool

Morgan Stanley believes that falling oil prices, easing rate expectations, and semiconductor normalization together are shifting U.S. equities from an AI-semiconductor leadership narrative to a broader set of lagging sectors.

This report is not a single-stock rating note; the core view is constructive on internal market rotation in U.S. equities, cautious on short-term semiconductor momentum, and preferring Consumer Discretionary Goods, Transportation, Biotechnology, and Hyperscalers.
U.S. Equity StrategyMarket DiffusionWeakening Semiconductor MomentumHyperscalersConsumer Discretionary GoodsTransportationBiotechnologyRate Expectations
  • Semiconductors have begun to underperform after a historic rise, and the report argues this helps rotate capital from a narrow set of AI-capex beneficiaries to broader market leadership.
  • The sharp drop in oil prices helps stabilize interest rates, and alongside softer employment data and lower inflation risk, it could ease markets' overly hawkish policy-rate expectations.
  • The report continues to prefer Consumer Discretionary Goods, Transportation, Regional Banks, and Biotechnology, with Consumer Discretionary Goods seen as the most attractive risk-reward expression of the rotation trade.
  • The report suggests that in the near term Hyperscalers are preferable to semiconductors, arguing Hyperscalers have already reflected the risk of slower capex growth and remain attractive due to optionality within the AI ecosystem.

Report interpretation

Overview

This weekly report focuses on the broadening of U.S. market leadership. Morgan Stanley reiterates a view first put forward in November 2025 and reaffirmed in the June 2026 midpoint outlook: in the context of a new expansion cycle, improving operating leverage, lower oil prices, and expected cooling in policy-rate expectations, market performance is expected to spread from a small set of AI-capex beneficiaries to more cyclical and rate-sensitive sectors. The report also notes that semiconductor momentum has weakened after a sharp run-up and that this may become an important catalyst for the rotation trade to continue evolving.

Core views

The core views include: first, the breadth of semiconductor EPS revisions remains near historical highs, and momentum decline and price re-pricing may not have ended yet, especially in the more commodity-like storage sub-industry. Second, falling oil prices, lower inflation risk, and weaker employment data may cool the market's expectations for Federal Reserve tightening or hawkish policy, benefiting a broader equity market. Third, Consumer Discretionary Goods, Transportation, Regional Banks, and Biotechnology are the main beneficiaries of the rotation trade, with Consumer Discretionary Goods benefiting from a shift in wallet share from services to goods, improved commodity pricing, and strengthening EPS normalization. Fourth, Hyperscalers are preferred over semiconductors in the near term because their valuations have already discounted slower capex growth risk while retaining core business, AI application-layer participation, and cost-reduction potential.

Analysis framework

The report uses a top-down U.S. equity strategy framework that integrates macro variables, rate expectations, oil prices, corporate earnings revisions, relative sector performance, and the AI capex cycle. The authors analyze relative performance between semiconductors and Hyperscalers, track the trend in high-capex-to-sales factor, monitor the breadth of EPS revisions, and incorporate historical biotech outperformance during falling-rate environments to assess market rotation direction.

Methodology notes

  • Macro and StrategyMarket Leadership Diffusion Framework

    Market leadership diffusing from a small set of large AI beneficiaries to broader lagging sectors

    The report argues that as the economy enters a new expansion phase, oil prices fall, and policy-rate expectations cool, earnings improvement can spread from narrow leaders to more sectors, allowing equal-weight indices and lagging cyclical sectors to benefit relatively.

  • Earnings RevisionsEPS Revision Breadth

    Using the breadth of earnings upgrades to gauge whether a sector's momentum has peaked or is improving

    Semiconductor EPS revision breadth is near historical highs and is viewed as a signal that short-term momentum may have peaked; improving EPS revision breadth in Consumer Discretionary Goods and Transportation supports the rotation trade.

  • Factor AnalysisHigh Capex-to-Sales Factor

    Observing relative performance of stocks with relatively high capital expenditure intensity

    After being strong over the past year, the high-capex-to-sales factor has started to plateau, which the report interprets as potentially making Hyperscalers more cautious on capex guidance and prompting the market to reassess the semiconductor beneficiary chain.

  • Rate SensitivitySector Performance in a Falling-Rate Phase

    Identifying industries that are sensitive to declining rates

    The report notes that biotechnology has historically achieved close to 20% annual returns in a high but declining-rate environment, giving it attractive risk-reward under cooling rate expectations.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

  • Semiconductors
    Short-term relatively cautious
    Strengths
    Still within the long-term AI capex cycle, with a strong history of EPS upgrades and price performance.
    Weaknesses
    Momentum has started to weaken after overheating, and EPS revision breadth is elevated; storage and similar sub-sectors are more exposed to commodity-cycle volatility.
    Comparison
    Compared with Hyperscalers, semiconductors are more dependent on continued acceleration in Hyperscaler capex, making them more vulnerable when capex expectations cool.
    Risks
    If AI demand continues to exceed expectations and capex guidance rises rather than declines, semiconductor normalization could be smaller than the report expects.
  • Hyperscalers
    Short-term relative preference
    Strengths
    They have strong core businesses, AI application-layer build and execution capabilities, and potential cost-reduction leverage.
    Weaknesses
    They still face market skepticism on capex growth and uncertainty around monetization paths for excess compute capacity.
    Comparison
    The report views Hyperscalers as having already gone through a period of underperformance and early risk pricing, making them relatively preferable to semiconductors in the near term.
    Risks
    If capex rises rapidly again and returns are not clear, valuations could come under pressure again.
  • Consumer Discretionary Goods
    One of the preferred rotation trades
    Strengths
    Benefits from a wallet-share shift from services to goods, improved goods pricing, and strengthening EPS normalization.
    Weaknesses
    Sensitive to consumer spending and macroeconomic growth.
    Comparison
    The report sees Consumer Discretionary Goods as the most attractive risk-reward expression of the rotation trade.
    Risks
    If labor or income conditions deteriorate significantly, the improvement in consumption demand could be constrained.
  • Transportation
    Rotation beneficiary
    Strengths
    EPS revision breadth continues to improve, and the sector benefits from economic expansion and lower oil prices.
    Weaknesses
    Sensitive to the economic cycle, fuel costs, and freight demand.
    Comparison
    Similar to Consumer Discretionary Goods and Regional Banks, Transportation is viewed as a reflection of broader market leadership.
    Risks
    If oil rebounds or economic activity weakens, transportation performance may decline.
  • Biotechnology
    Beneficiary of falling-rate normalization
    Strengths
    Historically performs relatively strongly during declining-rate phases, and a warming M&A cycle may provide additional support.
    Weaknesses
    Industry valuation and funding conditions are sensitive to rate changes, and stock-specific R&D and regulatory risks are high.
    Comparison
    Compared with most growth industries, biotechnology is more sensitive to rate declines, making it more resilient when policy expectations cool.
    Risks
    If rates rise instead of fall, M&A activity slows, or regulatory events increase, relative sector performance could weaken.

Key data

  • Report Date2026-07-06The cover shows July 6, 2026 04:01AM GMT.
  • Preferred SectorsConsumer Discretionary Goods, Transportation, Regional Banks, Biotechnology, HyperscalersThe report identifies these as the primary expressions of the market rotation trade.
  • Cautious DirectionSemiconductors, especially commodity-like sub-sectors such as storageSemiconductors have seen weakening momentum after a historical run-up, and the report believes further normalization remains possible.
  • Inflation AssumptionCore CPI below 3%The report cites Morgan Stanley internal views that core CPI this year will remain contained.
  • Biotech Historical PerformanceClose to 20% annualized returnThe report says biotechnology has historically shown strong returns in a higher-but-falling-rate environment.
  • Rating Distribution TableCovers 3,668 stocks; Overweight/Buy 42%, Equal-weight/Hold 43%, Underweight/Sell 15%From Morgan Stanley's disclosed global stock rating distribution, as of June 30, 2026.

Impact & implications

If the report's thesis is correct, investors may need to reduce reliance on the semiconductor single-lead narrative and shift toward more balanced sector allocation, especially with a focus on equal-weight indices, cyclical lagging sectors, and rate-sensitive industries. For the AI chain, this does not imply the end of the capex cycle, but a phase rotation within the cycle: semiconductors may come under pressure while Hyperscalers and broader application-layer opportunities look relatively more attractive.

Risks

  • If oil prices rise again, the narrative of rate stability and cooling inflation could weaken, and the rotation trade could be interrupted again.
  • If the Federal Reserve or market rate expectations turn hawkish again, rate-sensitive sectors such as Biotechnology and Regional Banks may come under pressure.
  • If AI capex continues to expand faster than expected, semiconductors may quickly regain leadership and the expected rotation could be delayed.
  • Large-cap semiconductor names have high weights in major indices, so semiconductor pullbacks may cause near-term broad market volatility or weakness, even if internal rotation continues.
  • Further deterioration in employment data could shift from a rate-positive to a growth-concern signal, affecting cyclical and consumption-related sectors.

What to watch

  • Whether semiconductor EPS revision breadth continues to decline from elevated levels.
  • Whether Hyperscalers lower or slow their capex growth guidance.
  • Oil price path and its impact on inflation and rate expectations.
  • Whether Federal Reserve communication, labor data, and core CPI support cooling rate expectations.
  • Whether Consumer Discretionary Goods, Transportation, Regional Banks, and Biotechnology continue to outperform the S&P 500 on a relative basis.
  • Whether the high capex-to-sales factor continues to plateau or turns weaker.
Zhejiang ICP No. 2022035445-5
Disclaimer: Market data, charts, indicators, research views, and other information provided on this website are intended solely for information display, research communication, and educational reference. They should not be regarded as personalized investment advice, securities recommendations, trading instructions, solicitations, or guarantees of return. While we strive to improve the reliability of our data and content, such information may still be subject to delays, errors, incompleteness, or untimely updates due to source differences, methodological limitations, system processing, or market volatility. Users should exercise independent judgment based on their own circumstances and bear all risks and responsibilities arising from the use of this website.

Settings

Sign in to view recent logins